RxDoctor Payments Data

Elizabeth Zook, APRN

Family · Rockford, ILNPI 1215496914

Payments from drug & device makers

$2,269in general payments, 2019–2025

Across 43 payments — averaging $52.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Amgen$286
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$205
  • Boston Scientific$148
  • Lexicon Pharmaceuticals, Inc.$121
  • Novartis$44
  • plus $114 from 4 others

What the payments were for

  • Travel & lodging$68030%
  • Food & beverage$1,45864%
  • Education$1306%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,269 in reported general payments places this provider in the 85th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$39,079
Medicare patients
288
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$131,755
EntrestoSacubitril/Valsartan78$88,966
XareltoRivaroxaban51$63,031
JardianceEmpagliflozin35$40,495
BrilintaTicagrelor23$22,232
Ezetimibe145$2,168
Atorvastatin Calcium266$2,071
Metoprolol Succinate195$1,978
ClopidogrelClopidogrel Bisulfate161$1,699
Rosuvastatin Calcium156$1,648
Carvedilol215$1,496
Amlodipine Besylate176$1,306
Isosorbide Mononitrate ErIsosorbide Mononitrate112$1,281
Lisinopril134$1,159
Prasugrel Hcl11$1,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$44$88,96678 claims
Johnson & JohnsonXarelto$38$63,03151 claims
Boehringer IngelheimJardiance$32$40,49535 claims
AstraZenecaBrilinta$26$22,23223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,941 family providers in Illinois.

Other family in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →